DERM · Journey Medical Corp
$6.69
+0.08 (+1.21%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, as a result of recurring and historical losses, substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements.”View the 10-Q filed Aug 12, 2026
Market Cap
$188.54M
Shares
28.22M
Volume · Oct 5
46.77K
Avg daily vol (3M)
184.12K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.61
Open$6.83
Day$6.47–6.88
52W close$4.39–9.26
Avg vol 30d163K
Short int2.9M · 10.4% float · 22.5d
Short vol55%
Last earningsAug 12, 2026
DataNov 2021–Oct 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Nov 12, 2026
Est · unconfirmed
· in 5 wks
filed Aug 12, 2026
call held Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$68.18M
Trailing 12 months
Net income (TTM)
−$6.10M
Trailing 12 months
Revenue growth YoY
+23.3%
Year over year
Operating margin
-4.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$171,000
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+18.0%
Year over year · more shares
Price change (1Y)
-9.5%
Trailing year
Short interest
10.4%
Latest settlement · 22.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−4%
below
Price vs 50-day avg
−5%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
46%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−16%
trailing
6-month return
+27%
trailing
YTD return
−14%
this year
Relative strength
+15%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $7 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.37% of float · ▼ -1.1% MoM · 22.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
71 holders — mid 3-yr range
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
+10%
Y/Y
EPS growth
+35%
Y/Y
Balance sheet
$1.2M
net debt
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−53%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−4%
Neutral
Price vs 50-day avg
−5%
Neutral
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
46%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $7 › 200d $7 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.37% of float · ▼ -1.1% MoM · 22.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
71 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4
Now $7 · 46%
Range high $9
vs 200-day avg -4%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| EBITDA | $1.42M | Q2 2026 | — |
| Emrosi® total prescriptions (TRx) | 36,000 | Q2 2026 | — |
| Non-GAAP Adjusted EBITDA non-GAAP | $3.49M | Six-Month Period Ended June 30, 2026 | — |
| Non-GAAP Adjusted EBITDA per common share (Basic) non-GAAP | $0.13 | Six-Month Periods Ended June 30, 2026 | — |
|
|
|||
| Non-GAAP Adjusted EBITDA per common share (Diluted) non-GAAP | $0.12 | Six-Month Periods Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DERM
this stock
Journey Medical Corp
|
$188.54M | -14.3% | +10.2% | — | 10.4% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.7% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DERM | +7.7% | -16.3% | +27.1% | -3.4% | -14.3% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +7.9% | -15.9% | +14.9% | -4.3% | -27.1% |